WO2002049627A2 - Antifungal compositions containing an antibiotic and one or more amidoamines - Google Patents

Antifungal compositions containing an antibiotic and one or more amidoamines Download PDF

Info

Publication number
WO2002049627A2
WO2002049627A2 PCT/US2001/043559 US0143559W WO0249627A2 WO 2002049627 A2 WO2002049627 A2 WO 2002049627A2 US 0143559 W US0143559 W US 0143559W WO 0249627 A2 WO0249627 A2 WO 0249627A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
hydrogen
natamycin
topically active
tridecyl
Prior art date
Application number
PCT/US2001/043559
Other languages
French (fr)
Other versions
WO2002049627A3 (en
Inventor
Gerald D. Cagle
Barry A. Schlech
Joseph W. Hiddemen
G. Michael Wall
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Priority to AU2002226926A priority Critical patent/AU2002226926A1/en
Publication of WO2002049627A2 publication Critical patent/WO2002049627A2/en
Publication of WO2002049627A3 publication Critical patent/WO2002049627A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Definitions

  • the present invention is directed to improved compositions and therapies for treating or preventing fungal infections.
  • the invention is particularly directed to the topical treatment or prevention of ophthalmic, otic and nasal infections, as well as to the sterilization of these tissues.
  • a topical ophthalmic composition containing natamycin is marketed under the name
  • NATACYN® natamycin ophthalmic suspension, USP
  • Sterile by Alcon Laboratories
  • the present invention is directed to the use of certain amidoamines to enhance or supplement the antifungal activity of natamycin or other antibiotics.
  • the amidoamines enhance the antifungal activity of natamycin and other antibiotics, but also provide some antibacterial activity.
  • the amidoamines are relatively nontoxic to delicate tissues, particularly corneal tissues, but also the mucosal tissues of the ear, nose and throat. This lack of toxicity enables the compositions of the present invention to achieve a significantly higher degree of control of fungal infections without creating the risk of toxicological side effects that might otherwise undermine the overall efficacy of the compositions.
  • the relative mildness of the amidoamines is particularly an advantage in patients whose ophthalmic, otic or nasal tissues have been compromised by means of a surgical procedure, physical injury or infection.
  • compositions utilized in the present invention comprise one or more topically active antibiotics, one or more amidoamines, and a pharmaceutically acceptable vehicle for these agents.
  • the compositions are formulated in a manner suitable for topical application to ophthalmic, otic or nasal tissues.
  • the antibiotics utilized in the present invention may be generally described as being selected from the group consisting of aminoglycosides, quinolones and natamycin.
  • the aminoglycosides and quinolones are both well-known classes of antibiotics. Examples of aminoglycoside antibiotics that may be utilized include tobramycin, gentamicin, framycetin and gramicidin. Examples of quinolone antibiotics that may be utilized include ciprofloxacin, moxifloxacin, ofloxacin, gatifloxacin, levofloxacin, norfloxacin, enterofloxacin and trovafloxacin.
  • natamycin is also a well-known antibiotic. However, unlike the aminoglycoside and quinolone antibiotics mentioned above, the prior usage of natamycin has been primarily directed to the topical treatment of fungal infections.
  • the present invention is directed to advancing the state of the art in the field of topical therapies for fungal infections of the eye, ear, nose and throat. Consequently, the use of an antibiotic that is particularly well suited for treating fungal infections is preferred.
  • the use of natamycin in the compositions and methods of the present invention is preferred for this reason.
  • the basic principle of the present invention which is that the amidoamines described herein may be utilized to enliance or supplement the antifungal activity of antibiotics, is also applicable to antibiotics other than natamycin, such as those described above.
  • amidoamines utilized in the present invention comprise one or more compounds of the following formula, or pharmaceutically acceptable salts thereof (e.g., hydrohalide salts):
  • Z is oxygen or NR 4 ;
  • R 1 is C 6 - C 18 saturated or unsaturated alkyl, alkylaryl, or alkoxyaryl; m is zero to 16; n is 2 to 16;
  • R , R , and R are independently hydrogen, Ci - C 8 saturated or unsaturated alkyl or hydroxyalkyl, or a pharmaceutically acceptable salt thereof.
  • amidoamine is Compound No. 4, which is known as N,N-Dimethyl-N'-
  • Compound No. 4 is available as MIRISTOCOR ® . myristamidopropyl dimethylamine phosphate, from Hoffman-La Roche Inc., Nutley, New Jersey (USA), and as Schercodine M from Scher Chemicals Inc., Clifton, New Jersey (USA); Compound No. 5 is available as LEXAMINE ® L-13, lauramidopropyl dimethylamine, from Inolex Chemical Company, Philadelphia, Pennsylvania (USA); and Compound No. 1 is available as LEXAMINE ® S-13, stearamidopropyl dimethylamine, also from Inolex Chemical Company.
  • amidoamines can be synthesized in accordance with known techniques, including those described in U.S. Patent No. 5,573,726 (Dassanayake, et al.), the entire contents of which are hereby incorporated in the present specification by reference. Examples of general reaction schemes which may be utilized are provided below.
  • A is a good leaving group, such as chloride or N- hydroxysuccinimide.
  • compositions of the present invention contain one or more topically active antibiotics and one or more amidoamines of formula (I).
  • the compositions may also contain other antimicrobial agents.
  • the compositions may contain cationic antiseptics.
  • Suitable cationic antiseptics include biguanides, such as chlorhexidine and
  • topically active antibiotic and the amount of amidoamines of formula (I) utilized in the compositions of the present invention will depend on the purpose of the use, e.g., the treatment of an active infection, the prophylactic treatment of tissues to prevent an active infection from developing, or the sterilization of tissues in conjunction with a medical procedure, such as a surgical procedure.
  • the amounts utilized will also depend on the particular tissues being treated. For example, lower concentrations will typically be utilized to treat especially sensitive tissue, such as the eye, while somewhat higher concentrations may be utilized to treat less sensitive tissues, such as the nose.
  • concentrations determined to be necessary for the above-stated purposes can be functionally described as "an antiinfective amount", "an antimicrobial effective amount” or variations thereof.
  • the amounts of topically active antibiotics utilized will generally be in the range of from about 0.5 to about 10.0 weight/volume percent (w/v%), and the amounts to amidoamines utilized will generally be in the range of about 0.00001 to about 0.1 w/v%.
  • compositions may be aqueous or nonaqueous, but will generally be aqueous.
  • compositions may contain a wide variety of ingredients, such as tonicity agents (e.g., sodium chloride or mannitol), surfactants (e.g., polyoxyethylene/polyoxypropylene copolymers.
  • viscosity adjusting agents e.g., hydroxypropyl methyl cellulose and other cellulose derivatives
  • buffering agents e.g., borates, citrates, phosphates ' and carbonates.
  • ophthalmic compositions intended for direct application to the eye will be formulated so as to have a pH and tonicity which are compatible with the eye. This will normally require a buffer to maintain the pH of the composition at or near physiologic pH (i.e., 7.4) and may require a tonicity agent to bring the osmolality of the composition near to 300 milliosmoles.
  • the following formulation is an example of an aqueous suspension of the present invention. This formulation is suitable for topical application as a drop or spray to the eye, ear, nose or throat.
  • Example 3 The following formulation is an example of an aqueous gel of the present invention. This formulation is suitable for. topical application to the eye, ear, nose or throat.
  • the following formulation is an example of an ointment of the present invention. This formulation is suitable for topical application to the eye, ear, nose or throat.
  • the following formulation is an example of a powder of the present invention. This formulation is suitable for topical application to the eye, ear, nose or throat.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Antimicrobial compositions containing one or more topically active antibiotics (e.g., Natamycin) and one or more amidoamines are described. The amidoamines enhance or supplement the antimicrobial activity of natamycin or other topically active antibiotics. The compositions are particularly useful in treating or preventing fungal infections of the eye, ear, nose and throat, as well as sterilizing these tissues prior to surgery or other medical procedures.

Description

ANTIFUNGAL COMPOSITIONS CONTAINING AN ANTIBIOTIC
AND ONE OR MORE AMIDOAMINES
Background of the Invention
The present invention is directed to improved compositions and therapies for treating or preventing fungal infections. The invention is particularly directed to the topical treatment or prevention of ophthalmic, otic and nasal infections, as well as to the sterilization of these tissues.
There are few effective therapies for treating fungal infections of the eyes, ears, nose, or throat. The antibiotic natamycin is currently utilized to treat ophthalmic fungal infections. A topical ophthalmic composition containing natamycin is marketed under the name
NATACYN® (natamycin ophthalmic suspension, USP) 5% Sterile by Alcon Laboratories,
Inc., Fort Worth, Texas.
Although the topical ophthalmic use of natamycin has generally proven to be effective in containing fungal infections, there is a need for improved therapies to treat and prevent fungal infections of the eye, ear, nose and throat. Summary of the Invention
The present invention is directed to the use of certain amidoamines to enhance or supplement the antifungal activity of natamycin or other antibiotics. The amidoamines enhance the antifungal activity of natamycin and other antibiotics, but also provide some antibacterial activity. Moreover, the amidoamines are relatively nontoxic to delicate tissues, particularly corneal tissues, but also the mucosal tissues of the ear, nose and throat. This lack of toxicity enables the compositions of the present invention to achieve a significantly higher degree of control of fungal infections without creating the risk of toxicological side effects that might otherwise undermine the overall efficacy of the compositions. The relative mildness of the amidoamines is particularly an advantage in patients whose ophthalmic, otic or nasal tissues have been compromised by means of a surgical procedure, physical injury or infection.
Description of Preferred Embodiments
The compositions utilized in the present invention comprise one or more topically active antibiotics, one or more amidoamines, and a pharmaceutically acceptable vehicle for these agents. The compositions are formulated in a manner suitable for topical application to ophthalmic, otic or nasal tissues.
The antibiotics utilized in the present invention may be generally described as being selected from the group consisting of aminoglycosides, quinolones and natamycin. The aminoglycosides and quinolones are both well-known classes of antibiotics. Examples of aminoglycoside antibiotics that may be utilized include tobramycin, gentamicin, framycetin and gramicidin. Examples of quinolone antibiotics that may be utilized include ciprofloxacin, moxifloxacin, ofloxacin, gatifloxacin, levofloxacin, norfloxacin, enterofloxacin and trovafloxacin.
As indicated above, natamycin is also a well-known antibiotic. However, unlike the aminoglycoside and quinolone antibiotics mentioned above, the prior usage of natamycin has been primarily directed to the topical treatment of fungal infections.
The present invention is directed to advancing the state of the art in the field of topical therapies for fungal infections of the eye, ear, nose and throat. Consequently, the use of an antibiotic that is particularly well suited for treating fungal infections is preferred. The use of natamycin in the compositions and methods of the present invention is preferred for this reason. However, the basic principle of the present invention, which is that the amidoamines described herein may be utilized to enliance or supplement the antifungal activity of antibiotics, is also applicable to antibiotics other than natamycin, such as those described above.
The amidoamines utilized in the present invention comprise one or more compounds of the following formula, or pharmaceutically acceptable salts thereof (e.g., hydrohalide salts):
Rl -(OCH2CH2)m-X-(CH2)n- Y (I)
wherein:
Figure imgf000005_0001
Figure imgf000005_0002
Z is oxygen or NR4 ;
R1 is C6 - C18 saturated or unsaturated alkyl, alkylaryl, or alkoxyaryl; m is zero to 16; n is 2 to 16;
R , R , and R are independently hydrogen, Ci - C8 saturated or unsaturated alkyl or hydroxyalkyl, or a pharmaceutically acceptable salt thereof.
The compounds wherein m is 0 to 5, n is 2 to 4, R is hydrogen or methyl, R is methyl or ethyl, and R4 is hydrogen, methyl or hydroxyethyl are particularly preferred, as are the compounds of Table 1:
Table 1;
COMPD. R1 M a X R2 Y R3 R4
NO.
1 Cl7 0 3 CONR2 H N(R3)2 CH3
2 C13 0 2 CONR2 H N(R3)2 CH3
3 C13 0 2 CONR2 H N(R3)2 C2H5
4 C13 0 3 CONR2 H N(R3)2 CH3
5 Cii 0 3 CONR2 H N(R3)2 CH3
6 Cπ 0 3 CONR2 H N(R3)2 C2H5
Figure imgf000006_0001
10 C13 0 3 CONR2 CH3 N(R3)2 CH3
11 Cl3 0 3 CONR2 H / \ N C2H4θH N Z
\ /
12 Cl2 5 3 CONR2 H N(R3)2 CH3
13 C12 4 2 R2NCO H N(R3)2 CH3
14 c12 0 3 CONR2 H N(R3)2 CH3
15 Cn 0 3 CONR2 CH3 N(R3)2 CH3
16 Cπ 0 3 CONR2 H / \ N C2H4θH N Z
\ /
Figure imgf000006_0002
The most preferred amidoamine is Compound No. 4, which is known as N,N-Dimethyl-N'-
tetradecanoyl-l,3-propylenediamine or N-[3-(Dimethylamino)propyl] tetradecanamide. This
compound may also be referred to by means of CAS Number 45267-19-4. Some of the amidoamines utilized in the present invention are available from commercial sources. For example, Compound No. 4 is available as MIRISTOCOR®. myristamidopropyl dimethylamine phosphate, from Hoffman-La Roche Inc., Nutley, New Jersey (USA), and as Schercodine M from Scher Chemicals Inc., Clifton, New Jersey (USA); Compound No. 5 is available as LEXAMINE® L-13, lauramidopropyl dimethylamine, from Inolex Chemical Company, Philadelphia, Pennsylvania (USA); and Compound No. 1 is available as LEXAMINE® S-13, stearamidopropyl dimethylamine, also from Inolex Chemical Company.
The above-described amidoamines can be synthesized in accordance with known techniques, including those described in U.S. Patent No. 5,573,726 (Dassanayake, et al.), the entire contents of which are hereby incorporated in the present specification by reference. Examples of general reaction schemes which may be utilized are provided below.
Scheme I;
The following reaction scheme may be utilized to synthesize compounds wherein
X is CONR2 :
Figure imgf000007_0001
In the foregoing reaction scheme, A is a good leaving group, such as chloride or N- hydroxysuccinimide.
Scheme II: The following reaction scheme may be utilized to synthesize compounds wherein X is NR2CO :
Figure imgf000008_0001
The following article may be referred to for further details concerning the Scheme I synthesis of the amidoamines of formula (I): Muzyczko, et al., "Fatty Amidoamine Derivatives: N,N-Dimethyl-N-(3-alkylamidopropyl)amines and Their Salts", Journal of the American Oil Chemists' Society, volume 45, number 11, pages 720-725 (1968).
The compositions of the present invention contain one or more topically active antibiotics and one or more amidoamines of formula (I). The compositions may also contain other antimicrobial agents. For example, the compositions may contain cationic antiseptics.
Examples of suitable cationic antiseptics include biguanides, such as chlorhexidine and
PHMB, and quaternary-ammonium compounds, such as benzalkonium chloride and polyquaternium. The amount of topically active antibiotic and the amount of amidoamines of formula (I) utilized in the compositions of the present invention will depend on the purpose of the use, e.g., the treatment of an active infection, the prophylactic treatment of tissues to prevent an active infection from developing, or the sterilization of tissues in conjunction with a medical procedure, such as a surgical procedure. The amounts utilized will also depend on the particular tissues being treated. For example, lower concentrations will typically be utilized to treat especially sensitive tissue, such as the eye, while somewhat higher concentrations may be utilized to treat less sensitive tissues, such as the nose. The concentrations determined to be necessary for the above-stated purposes can be functionally described as "an antiinfective amount", "an antimicrobial effective amount" or variations thereof. The amounts of topically active antibiotics utilized will generally be in the range of from about 0.5 to about 10.0 weight/volume percent (w/v%), and the amounts to amidoamines utilized will generally be in the range of about 0.00001 to about 0.1 w/v%.
The above-described topically active antibiotics and amidoamines of formula (I) may be included in various types of pharmaceutical compositions, including solutions, suspensions, gels, ointments, creams, sprays and powders. The compositions may be aqueous or nonaqueous, but will generally be aqueous. As will be appreciated by those skilled in the art, the compositions may contain a wide variety of ingredients, such as tonicity agents (e.g., sodium chloride or mannitol), surfactants (e.g., polyoxyethylene/polyoxypropylene copolymers. such as Poloxamine™), viscosity adjusting agents (e.g., hydroxypropyl methyl cellulose and other cellulose derivatives) and buffering agents (e.g., borates, citrates, phosphates ' and carbonates). The present invention is not
limited with respect to the types of pharmaceutical compositions in which the combination of one or more topically active antibiotics and one or more amidoamines of formula (I) may be utilized.
As will be appreciated by those skilled in the art, ophthalmic compositions intended for direct application to the eye will be formulated so as to have a pH and tonicity which are compatible with the eye. This will normally require a buffer to maintain the pH of the composition at or near physiologic pH (i.e., 7.4) and may require a tonicity agent to bring the osmolality of the composition near to 300 milliosmoles.
The following examples are presented to further illustrate methods of synthesizing the amidoamines of formula (I) and pharmaceutical compositions containing these compounds in combination with natamycin or other topically active antibiotics.
Example 1
Synthesis of N,N-Dimethyl-N'-Tetradecanoyl-l,3-PropyIenediamine (Compound No. 4")
2.0 g. (0.0196 moles) of 3-dimethylaminopropylamine in 40 ml chloroform was added dropwise to an ice cold chloroform solution (50 ml) of myristoyl chloride (4.17 g.5 0.0169 moles). After addition, the ice bath was removed and the solution was stirred for 2 hours. A 25 ml aqueous sodium bicarbonate solution was added and stirred for 30 minutes. The organic layer was then washed with 30 ml aqueous sodium bicarbonate/sodium chloride solution and dried with magnesium sulfate. The solution was concentrated in vacuo and the amide was recrystallized in ethyl acetate to yield 3.29 g. (0.0105 moles, 62.3%) of the subject
compound. 1H NMR (200 MHz, CDCL3): δ 6.9 (s, 1H, NH), 3.3 (q, 3H, NHCHj,), 2.4 (t, 2H, NCH2),
2.22 (s, 6H, NCH3), 2.15 (t, 2H, COCH2), 1.7-1.5 (m, 4H, COCH2CH2 and NHCH2CH2), 1.25 (s, 20H, COCH2CH2(CH2)io). 0.88 (t, 3H, CH3).
Elemental Analysis: Calculated for CigH^O (312.52): C, 73.02; H, 12.90; N, 8.96. Found: C, 72.96; H, 12.92; N, 8.93.
Example 2
The following formulation is an example of an aqueous suspension of the present invention. This formulation is suitable for topical application as a drop or spray to the eye, ear, nose or throat.
Ingredient Amount (w/v% Natamycin 5.0
Compound No. 4 0.005
Benzalkonuim Chloride 0.02
Glycerin 0 to 2.5
Mannitol 0 to 2.5 Hydroxypropyl Ethyl Cellulose 0 to 2.5
NaOH/HCl q.s. pH 7.4
Purified Water q.s. 100
Example 3 The following formulation is an example of an aqueous gel of the present invention. This formulation is suitable for. topical application to the eye, ear, nose or throat.
Ingredient Amount (w/v%)
Moxifloxacin 0.1 to 1.0
Natamycin 5.0
Compound No. 4 0.001 to 0.01
Boric Acid 0.3
Xanthan Gum 0.1 to 5.0
Sodium Chloride 0.64
NaOH/HCl q.s. . pH 4 to 8
Purified Water q.s, . 100
Examp - 4
The following formulation is an example of an ointment of the present invention. This formulation is suitable for topical application to the eye, ear, nose or throat.
Ingredient Amount (w/v%)
Natamycin 5.0
Compound No. 4 0.001 to 0.1
White Petrolatum 1 - 50
Boric Acid 0.3
Mineral Oil q.s. Example 5
The following formulation is an example of a powder of the present invention. This formulation is suitable for topical application to the eye, ear, nose or throat.
Ingredient Amount (weight %)
Natamycin 5.0 Compound No. 4 0.001 to 0.01
Moxifloxacin 0.1 to 1.0
Boric Acid q.s.

Claims

What is Claimed is:
1. A topical antimicrobial composition useful in the treatment and prevention of fungal infections of the eye, ear, nose and throat, comprising: an antiinfective amount of a topically active antibiotic; an antiinfective amount of an amidoamine of the formula:
Rl-(OCH2CH2)m-X-(CH2)n-Y (I)
wherein:
Figure imgf000014_0001
Z is oxygen or NR4 ;
R1 is C6 - Cis saturated or unsaturated alkyl, aikylaryl, or alkoxyaryl; m is zero to 16; n is 2 to 16;
R , R , and R are independently hydrogen, C\ - C8 saturated or unsaturated alkyl or hydroxyalkyl, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle therefor.
2. A composition according to Claim 1, wherein n is 2 to 4, and m is 0 to 5.
3. A composition according to Claim 2, wherein R2 is hydrogen or methyl, and R3 is methyl or ethyl.
4. A composition according to Claim 1, wherein R1 is heptadec-8-enyl, undecyl, undecenyl, dodecyl, tridecyl, tetradecyl, pentadecyl or heptadecyl, R2 is hydrogen or methyl, R3 is methyl or ethyl, and R4 is hydrogen, methyl or hydroxyethyl.
5. A composition according to Claim 1, wherein R1 is tridecyl, m is 0, n is 3, Y is N(R3)2 and R3 is methyl.
6. A composition according to Claim 1, wherein the topically active antibiotic is selected from the group consisting of aminoglycoside antibiotics, quinolone antibiotics, and natamycin.
7. A composition according to Claim 1, wherein the topically active antibiotic comprises natamycin.
8. A composition according to Claim 7, wherein R1 is tridecyl, m is 0, n is 3, y is N(R3)2 and R3 is methyl.
. A method of treating or preventing fungal infections of the eye, ear or nose, which comprises applying a topical pharmaceutical composition to the affected tissues, said composition comprising: an antiinfective amount of a topically active antibiotic; an antiinfective amount of a compound of the following formula:
Rl-(OCH2CH2)m-X-(CH2)n-Y (I)
wherein:
Figure imgf000016_0001
Figure imgf000016_0002
Z is oxygen or NR4 ;
R1 is C6 - C18 saturated or unsaturated alkyl, alkylaryl, or alkoxyaryl; m is zero to 16; n is 2 to 16; R2, R3, and R4 are independently hydrogen, C\ - C8 saturated or unsaturated alkyl or hydroxyalkyl. or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle therefor.
10. A method according to Claim 9, wherein n is 2 to 4, and m is 0 to 5.
11. A method according to Claim 10, wherein R2 is hydrogen or methyl, and R3 is
methyl or ethyl.
12. A method according to Claim 9, wherein R1 is heptadec-8-enyl, undecyl, undecenyl, dodecyl, tridecyl, tetradecyl, pentadecyl or heptadecyl, R2 is hydrogen or methyl, R3 is methyl or ethyl, and R4 is hydrogen, methyl or hydroxyethyl.
13. A method according to Claim 9, wherein R1 is tridecyl, m is 0, n is 3, Y is N(R3) 2 and R3 is methyl.
14. A method according to Claim 9, wherein the composition further comprises
0.00005 to 0.01 w/v% of polyquaternium-1.
15. A method according to Claim 9, wherein the topically active antibiotic is selected from the group consisting of aminoglycoside antibiotics, quinolone antibiotics, and natamycin.
16. A method according to Claim 9, wherein the topically active antibiotic comprises natamycin.
17. A method according to Claim 16, wherein R1 is tridecyl, m is 0, n is 3, y is N(R3)2 and R3 is methyl.
PCT/US2001/043559 2000-12-20 2001-11-21 Antifungal compositions containing an antibiotic and one or more amidoamines WO2002049627A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002226926A AU2002226926A1 (en) 2000-12-20 2001-11-21 Antifungal compositions containing an antibiotic and one or more amidoamines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25731000P 2000-12-20 2000-12-20
US60/257,310 2000-12-20

Publications (2)

Publication Number Publication Date
WO2002049627A2 true WO2002049627A2 (en) 2002-06-27
WO2002049627A3 WO2002049627A3 (en) 2003-05-01

Family

ID=22975752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/043559 WO2002049627A2 (en) 2000-12-20 2001-11-21 Antifungal compositions containing an antibiotic and one or more amidoamines

Country Status (2)

Country Link
AU (1) AU2002226926A1 (en)
WO (1) WO2002049627A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519695A (en) * 2010-02-19 2013-05-30 メガインファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング Drugs containing miramistin
US9114168B2 (en) 2008-06-09 2015-08-25 Alcon Pharmacueticals Ltd. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573726A (en) * 1993-09-22 1996-11-12 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
WO2000018386A2 (en) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573726A (en) * 1993-09-22 1996-11-12 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
WO2000018386A2 (en) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ILLINGWORTH CHRISTOPHER D ET AL: "Acanthamoeba keratitis." SURVEY OF OPHTHALMOLOGY, vol. 42, no. 6, May 1998 (1998-05), pages 493-508, XP002225020 ISSN: 0039-6257 *
MARTINDALE THE EXTRA PHARMACOPOEIA, 30TH EDITION: "Natamycin" , THE PHARMACEUTICAL PRESS , LONDON, UK XP002225449 page 329, right-hand column, paragraph 3 -page 330, left-hand column, paragraph 1 *
RAHMAN M R ET AL: "Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh." THE BRITISH JOURNAL OF OPHTHALMOLOGY. ENGLAND AUG 1998, vol. 82, no. 8, August 1998 (1998-08), pages 919-925, XP002225443 ISSN: 0007-1161 *
ROSENTHAL R A ET AL: "BROAD SPECTRUM ANTIMICROBIAL ACTIVITY OF A NEW MULTI-PURPOSE DISINFECTING SOLUTION" CLAO JOURNAL, THE ASSOCIATION, ST. LOUIS, MO, US, vol. 26, no. 3, July 2000 (2000-07), pages 120-126, XP008011165 ISSN: 0733-8902 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114168B2 (en) 2008-06-09 2015-08-25 Alcon Pharmacueticals Ltd. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
JP2013519695A (en) * 2010-02-19 2013-05-30 メガインファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング Drugs containing miramistin

Also Published As

Publication number Publication date
AU2002226926A1 (en) 2002-07-01
WO2002049627A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
AU701069B2 (en) Use of amidoamines in ophthalmic compositions
US5631005A (en) Use of amidoamines in ophthalmic compositions
US6664294B1 (en) Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
US7871602B2 (en) Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
EP0669803B1 (en) Use of amidoamines in ophthalmic compositions
US6936640B2 (en) Biguanide/quaternary ammonium containing copolymeric biocides and use thereof in pharmaceutical compositions
US7025958B2 (en) Use of amidoamines to treat or prevent acanthamoeba and fungal infections
US20040033208A1 (en) Antifungal compositions containing an antibiotic and one or more amidoamines
WO2002049627A2 (en) Antifungal compositions containing an antibiotic and one or more amidoamines
US5627214A (en) Use of diamines in ophthalmic compositions
JPH06316519A (en) Use of specific sulfamoyl-substituted phenethylamine derivative for suppressing corediastasis induced by medicine or reducing expanded pupil and local dose composition used therefor
US5900213A (en) Use of diamines to disinfect and clean contact lenses and preserve ophthalmic compositions
IE903406A1 (en) Antimicrobial compositions
MXPA96005188A (en) Use of amidoamines in oftalmi compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10432427

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP